A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study of Sevelamer Carbonate in CKD Patients on Hemodialysis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study of Sevelamer Carbonate in CKD Patients on Hemodialysis

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs Sevelamer (Primary)
  • Indications Hyperphosphataemia
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation; Sanofi
  • Most Recent Events

    • 01 Apr 2014 New trial record
    • 01 Sep 2010 Primary endpoint 'Phosphate-levels' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top